TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06391502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component Exercise Intervention Program
Description: The Vivifrail program (http://vivifrail.com) is a home-based exercise program that focuses on personalized multi-component exercise prescriptions based on an elderly person's functional abilities, including resistance/strength, balance, flexibility, and cardiovascular endurance exercise (i.e., walking).~During hospitalization, patients who meet the criteria of sodium intake will be screened, and then divided into groups according to the method of randomized controlled trial. The experimental group will carry out corresponding exercise plan according to the results of SPPB.
Study: NCT06328426

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The dose of Vitamin D will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The dose of Vitamin D will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: The dose of omega-3 will be 1000 mg /day taken orally. The duration of the intervention will be 4 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The dose of metformin will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The duration of the intervention will be 4 months.
Study: NCT05239351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jalucomplex
Description: Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jalucomplex
Description: Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jalucomplex
Description: Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
Study: NCT04744051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 Adipose Derived Stem Cell Infusion
Description: Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 Adipose Derived Stem Cell Infusion
Description: Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 Adipose Derived Stem Cell Infusion
Description: Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
Study: NCT05857631

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Image guided External Beam Radiation Therapy (EBRT)
Description: External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
Study: NCT05166460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney cooling device
Description: renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
Study: NCT05937139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: Breastfeeding education will be given to fathers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: Breastfeeding education will be given to fathers.
Study: NCT05793918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Percutaneous Electrolysis an neuromodulation
Description: Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
Study: NCT05139290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prototype Intervention
Description: The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
Study: NCT05057923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Description: Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis
Description: Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
Study: NCT04782843

Intervention type: OTHER
Intervention: HEP score assessement
Description: Assessement of the HEP score between 2 physician.
Study: NCT05381779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training Group
Description: Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training Group
Description: High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
Study: NCT06032936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
Study: NCT06401460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yannianjiuzhuan method combined with reverse breathing training
Description: Timing of Operations~1. Reverse Abdominal Breathing: Performed from 9:00 AM to 11:00 AM and from 7:00 PM to 9:00 PM daily, one inhalation and one exhalation constituting one cycle, with 30 cycles per training session, twice a day, over a period of ten days.~2. Yannian Jiuzhuan Method: Conducted daily from 7:00 AM to 9:00 AM and from 9:00 PM to 11:00 PM, twice a day, for a duration of ten days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yannianjiuzhuan method combined with reverse breathing training
Description: Timing of Operations~1. Reverse Abdominal Breathing: Performed from 9:00 AM to 11:00 AM and from 7:00 PM to 9:00 PM daily, one inhalation and one exhalation constituting one cycle, with 30 cycles per training session, twice a day, over a period of ten days.~2. Yannian Jiuzhuan Method: Conducted daily from 7:00 AM to 9:00 AM and from 9:00 PM to 11:00 PM, twice a day, for a duration of ten days.
Study: NCT04987723

Intervention type: OTHER
Group type: OTHER
Intervention: Holter monitoring
Description: Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Holter monitoring
Description: Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.

Intervention type: OTHER
Group type: OTHER
Intervention: stress echocardiography
Description: Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
Study: NCT05624385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
Study: NCT06094270

Intervention type: DEVICE
Intervention: EndoMind
Description: Withdrawal time is calculated and an image report is generated using the EndoMind system.
Study: NCT06389253

Intervention type: OTHER
Intervention: Histological Analysis
Description: For the study, a minimal part of the periarticular tissue, specifically the sinus tarsi juxta-articular fatty tissue, that is normally dissected and discarded during the surgical operation of insertion and removal of the calcaneo-stop screw, will be analyzed

Intervention type: OTHER
Intervention: Histological Analysis
Description: For the study, a minimal part of the periarticular tissue, specifically the sinus tarsi juxta-articular fatty tissue, that is normally dissected and discarded during the surgical operation of insertion and removal of the calcaneo-stop screw, will be analyzed
Study: NCT05199974

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline abdominal closure
Description: Abdominal Closure in Emergency Midline Laparotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline abdominal closure
Description: Abdominal Closure in Emergency Midline Laparotomy
Study: NCT04698369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Massage Therapy
Description: WearUL is a patent pending wearable rehabilitation technology that targets localized vibration massage therapy directly onto the body. The frequency and amplitude combinations to be delivered by WearUL are safe and effective in clinical and research settings based on previous studies on focal vibration.
Study: NCT05050253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super-oxidized solution (SOS)
Description: Peritoneal lavage with super-oxidized solution in patients undergoing emergency abdominal surgery for secondary peritonitis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's solution
Description: Peritoneal lavage with Ringer's solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
Study: NCT05997888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At-Home Strength Training Intervention
Description: A six-week strength training intervention in which participants will choose workouts to complete on their own. These workouts are 20-25 minutes light-intensity strength training with light strength bands. Exercises will have multiple options to account for various levels of ability. Additionally, there will be a group counseling session once per week via Zoom and a group strength training program.
Study: NCT04207866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconferencing
Description: Use of video/audio stream to provide auditory training at a remote site.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory training services
Description: Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory training services
Description: Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal.
Study: NCT04964414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell Retraining
Description: Smell practice with household scented items

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smell Retraining
Description: Smell practice with household scented items

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Nasal irrigation with liquid steroid
Study: NCT05949333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: long-acting granulocyte-colony stimulating factor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflapegrastim
Description: long-acting granulocyte-colony stimulating factor
Study: NCT06047015

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IRE plus checkpoint inhibitor
Description: Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IRE plus Checkpoint Inhibitor plus CpG-ODN
Description: Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al.
Study: NCT04951024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar interfacial plane (TLIP) Block
Description: TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracolumbar interfacial plane (TLIP) Block
Description: TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane (ESP) Block
Description: ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Description: ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
Study: NCT04515316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPM sensors
Description: Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPM sensors
Description: Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID sensors
Description: Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID sensors
Description: Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject